Female Infertility Diagnosis and Treatment Market to Reach $11.2 Billion by 2035

Female infertility diagnosis and treatment market was valued at an estimated $4.9 billion in 2025 and is projected to reach $11.2 billion by 2035, registering a stated CAGR of 8.7% during 2026–2035. The market includes diagnostic tests, fertility medicines, hormonal therapies, assisted reproductive technology (ART), medical devices, and related products used to evaluate and treat female infertility. Growing demand for reproductive healthcare, greater use of fertility assessments, and developments in assisted conception are creating opportunities for manufacturers of diagnostic and treatment products. According to the UK’s Human Fertilisation and Embryology Authority (HFEA), approximately 53,000 patients received IVF treatment at licensed UK clinics in 2024, illustrating the scale of clinical demand for fertility services. This treatment figure reflects activity in the UK rather than global market revenue.

Browse the full report description of “Female Infertility Diagnosis and Treatment Market Size, Share & Trends Analysis Report, By Diagnosis Type (Ovulation Testing, Hormone Testing, Ovarian Reserve Testing, Imaging Tests (Ultrasound), Hysterosalpingography (HSG), Hysteroscopy, Other Diagnostic Tests), By Treatment Type (Fertility Drugs and Hormonal Therapy, Assisted Reproductive Technology (ART), Surgical Treatment, Other Treatments), By ART (In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Sperm Injection (ICSI), Other ART Procedures), By Infertility Cause (Ovulatory Disorders, Polycystic Ovary Syndrome (PCOS), Endometriosis, Tubal Factor Infertility, Uterine Factor Infertility, Diminished Ovarian Reserve and Age-Related Infertility, Unexplained Infertility, Other Causes), By End User (Fertility Clinics and IVF Centers, Hospitals, Diagnostic Laboratories, Specialty Reproductive Health Centers, Other Healthcare Facilities), By Distribution Channel (Hospital and Clinic Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/female-infertility-market-size

The market is supported by advances in reproductive medicine, the availability of specialized fertility clinics, and growing efforts to make infertility assessment and treatment accessible earlier in the care pathway. Product innovation spans ovarian-stimulation medicines, ultrasound-based diagnostic systems, oocyte-retrieval devices, embryo culture products, and insemination technologies. Market performance, however, varies by country according to healthcare funding, regulatory requirements, patient affordability, and access to specialist services. Manufacturers are therefore pursuing product development, clinical research, distribution partnerships, and expansion into new care settings to strengthen their market presence.

IVF Segment to Gain Momentum with Advancements in Fertility Treatment and Embryo Technologies

The in vitro fertilization (IVF) segment represents a key growth opportunity within the Female Infertility Market because it uses a range of specialized products, including ovarian-stimulation medicines, oocyte-retrieval devices, culture media, laboratory consumables, and embryo-handling technologies. IVF may be recommended for different infertility-related conditions depending on clinical assessment and patient circumstances. The growing use of frozen embryo transfers and the continued development of reproductive laboratory technologies are supporting demand for products used across the IVF workflow. The HFEA reported that frozen embryo transfers accounted for 48% of IVF cycles carried out in the UK in 2024, highlighting the increasing role of frozen-transfer procedures in fertility treatment.

Competition in the IVF-related product segment focuses on product reliability, clinical evidence, laboratory workflow requirements, regulatory compliance, and access to healthcare providers. Pharmaceutical companies supply medicines used for ovarian stimulation, while reproductive technology manufacturers develop devices and consumables for retrieval, fertilization, embryo culture, and cryopreservation. Adoption of new products depends on clinical suitability, affordability, training requirements, and the capacity of fertility facilities to implement them. Although IVF is an important area of commercial activity, its status as the fastest-growing market segment cannot be confirmed without comparable segment-level revenue forecasts.

Recent Developments

• In August 2026, CooperSurgical announced FDA clearance for the Wallace Aspiration Pump, a fertility device designed to support controlled aspiration during oocyte retrieval. The pump features a digital touchscreen, preset pressure settings for different needle types, and customizable operating options. The clearance marks a product development milestone in assisted reproductive technology and supports the company’s expansion of fertility equipment for clinical use in the United States.

• In July 2025, researchers published results from Ferring Pharmaceuticals’ RITA-1 and RITA-2 randomized clinical trials evaluating Rekovelle (follitropin delta) for ovarian stimulation in women undergoing IVF or ICSI. The trials included 1,165 patients and reported cumulative ongoing pregnancy rates of 64.0% among women under 35 and 43.9% among women aged 35–42. The findings support the medicine’s role in ovarian stimulation and provide clinical evidence for fertility treatment across different age groups.

Market Coverage

• Market period: 2025–2035
• Base year: 2025
• Forecast period: 2026–2035
• Segments covered:
• Diagnosis Type
• Treatment Type
• Assisted Reproductive Technology
• Infertility Cause
• End User
• Distribution Channel
• Regions covered:
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape - CooperSurgical, Inc., Ferring Pharmaceuticals, Gedeon Richter Plc., Merck KGaA, and Vitrolife AB, among others.

Key questions addressed by the report:

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region are projected to grow fastest?
• Who are the leading market participants?
• How are players addressing challenges to sustain growth?
• Where are the investment opportunities?

Female Infertility Diagnosis and Treatment Market Report Segmentation

By Diagnosis Type

• Ovulation Testing
• Hormone Testing
• Ovarian Reserve Testing
• Imaging Tests (Ultrasound)
• Hysterosalpingography (HSG)
• Hysteroscopy
• Other Diagnostic Tests

By Treatment Type

• Fertility Drugs and Hormonal Therapy
• Assisted Reproductive Technology (ART)
• Surgical Treatment
• Other Treatments

By Assisted Reproductive Technology

• In Vitro Fertilization (IVF)
• Intrauterine Insemination (IUI)
• Intracytoplasmic Sperm Injection (ICSI)
• Other ART Procedures

By Infertility Cause

• Ovulatory Disorders
• Polycystic Ovary Syndrome (PCOS)
• Endometriosis
• Tubal Factor Infertility
• Uterine Factor Infertility
• Diminished Ovarian Reserve and Age-Related Infertility
• Unexplained Infertility
• Other Causes

By End User

• Fertility Clinics and IVF Centers
• Hospitals
• Diagnostic Laboratories
• Specialty Reproductive Health Centers
• Other Healthcare Facilities

By Distribution Channel

• Hospital and Clinic Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Female Infertility Diagnosis and Treatment Market Report Segmentation by Region

North America

• United States
• Canada

Europe

• United Kingdom
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Taiwan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/female-infertility-market-size